Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS)

CUSIP: 221015100

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class
Equity / Common Stock, par value $0.0001 per share
Total 13F shares
41,781,497
Total 13F value
$167,123,225
Holder snapshot 6 visible 7 signals
Share change
+5,508,366
Put/Call ratio
230%
SEC-reported price per share
$4.00
Number of holders
92
Value change
+$27,653,733
Number of buys
64
Open additional details 1 more signal available
Number of sells
38
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
91,091,040

Security key

221015100

Report period

Q2 2025

Institutions

92

Top holders

10

CRVS full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Previous quarter: Q1 2025 Corvus Pharmaceuticals, Inc. SEC filings Corvus Pharmaceuticals, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
27 Jun 2025
3/4/5 13F Lead comparable stake: 7.9% Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 7.9%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership Top 5
ORBIMED ADVISORS LLC 7.9%
SAMLYN CAPITAL, LLC 4.5%
ADAMS STREET PARTNERS LLC 3.6%
Point72 Asset Management, L.P. 3.1%
RTW INVESTMENTS, LP 2.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ORBIMED ADVISORS LLC
3/4/5 13F
Director, 10%+ Owner · Company
3/4/5 13F
7.9%
$29,796,393
7,165,006 shares
 -$4,891,894 27 Jun 2025
SAMLYN CAPITAL, LLC
13F
Company
13F
4.5%
$12,929,674
4,065,935 shares
 — 31 Mar 2025
ADAMS STREET PARTNERS LLC
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
3.6%
$10,416,459
3,275,616 shares
 — 31 Mar 2025
Point72 Asset Management, L.P.
13F
Company
13F
3.1%
$8,864,667
2,787,631 shares
 — 31 Mar 2025
RTW INVESTMENTS, LP
13F
Company
13F
2.9%
$8,520,743
2,679,479 shares
 — 31 Mar 2025
VANGUARD GROUP INC
13F
Company
13F
2.7%
$7,931,381
2,494,145 shares
 — 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
92
Shares
41,781,497
Rows available
92
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
87
Q2 2025 holders
92
Holder diff
5
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .